Dual Blockade of the Renin-Angiotensin System for Cardiorenal Protection: An Update

American Journal of Kidney Diseases

Volumn 53, Issue 2, 2009, Pages 332-345

  Arici, Mustafa ^a   Erdem, Yunus ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

angiotensin receptor blockers; angiotensin converting enzyme inhibitors; cardiovascular disease; chronic kidney disease; clinical trials; dual blockade; hypertension; proteinuria; Renin angiotensin system

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPROSARTAN; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; VALSARTAN;

BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; GENERAL PRACTICE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART PROTECTION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; KIDNEY FUNCTION; MONOTHERAPY; MORBIDITY; MORTALITY; ORTHOSTATIC HYPOTENSION; POTASSIUM BLOOD LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT; SUDDEN DEATH; UNSPECIFIED SIDE EFFECT; URINARY EXCRETION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; KIDNEY DISEASES; RENIN-ANGIOTENSIN SYSTEM;

EID: 58249108731     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2008.11.021     Document Type: Review

References (67)

1. Fyhrquist F., and Saijonmaa O. Renin-angiotensin system revisited. J Intern Med 264 (2008) 224-236
2. Cushman D.W., Cheung H.S., and Sabo E.F. Development and design of specific inhibitors of angiotensin-converting enzyme. Am J Cardiol 49 (1982) 1390-1394
3. Bhardwaj G. How the antihypertensive losartan was discovered. Expert Opin Drug Discov 1 (2006) 609-618
4. Lewington A.J., Arici M., Harris K.P.G., et al. Modulation of the renin-angiotensin system in proteinuric renal disease: are there added benefits?. Nephrol Dial Transplant 16 (2001) 885-888
5. Wolf G., and Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 67 (2005) 799-812
6. Matchar D.B., McCrory D.C., Orlando L.A., et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 148 (2008) 16-29
7. Weber M.A. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Am J Cardiol 100 (2007) 45J-52J
8. Unger T., and Stoppelhaar M. Rationale for double renin-angiotensin-aldosterone-system blockade. Am J Cardiol 100 (2007) 25J-31J
9. Cohn J.N., and Goldman J.M. Establishing a new option for target-organ protection: rationale for ARB plus ACE inhibitor combination therapy. Am J Hypertens 23 (2008) 248-256
10. van de Wal R.M.A., van Veldhuisen D.J., van Gilst W.H., et al. Addition of an angiotensin receptor blocker to full-dose ACE-inhibition: controversial or common sense?. Eur Heart J 26 (2005) 2361-2367
11. van de Wal R.M.A., Plokker H.W., Lok D.J., et al. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol 106 (2006) 367-372
12. Huang X.R., Chen W.Y., Truong L.D., and Lan H.Y. Chymase is upregulated in diabetic nephropathy: implications for an alternative pathway of angiotensin II-mediated diabetic renal and vascular disease. J Am Soc Nephrol 14 (2003) 1738-1747
13. Carey R.M. Update on the role of the AT2 receptor. Curr Opin Nephrol Hypertens 4 (2005) 67-71
14. Burnier M., and Brunner H.R. Angiotensin II receptor antagonists. Lancet 355 (2000) 637-645
15. Doulton T.W., He F.J., and MacGregor G.A. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 45 (2005) 880-886
16. Morgan T., Anderson A., Bertram D., and MacInnis R.J. Effect of candesartan and lisinopril alone and in combination on blood pressure and microalbuminuria. J Renin Angiotensin Aldosterone Syst 5 (2004) 64-71
17. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. New Engl J Med 358 (2008) 1547-1559
18. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension. J Hypertens 25 (2007) 1105-1187
19. Cohn J.N., Tognoni G., and Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 365 (2001) 1667-1675
20. McMurray J.J., Östergren J., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362 (2003) 767-771
21. Pfeffer M.A., McMurray J.J.V., Velazquez E.J., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. New Engl J Med 349 (2003) 1893-1906
22. Jneid H., Moukarbel G.V., Dawson B., et al. Combining neuroendocrine inhibitors in heart failure: reflections on safety and efficacy. Am J Med 120 (2007) 1090.e1-1090.e8
23. Lakhdar R., Al-Mallah M.H., and Lanfear D.E. Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials. J Card Fail 14 (2008) 181-188
24. Werner C., Baumhakel M., Teo K.K., et al. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin Res Cardiol 97 (2008) 418-431
25. Mann J.F.E., Schmieder R., McQueen M., et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372 (2008) 547-553
26. Sarafidis P.A., and Bakris G.L. Renin-angiotensin blockade and kidney disease. Lancet 372 (2008) 511-512
27. Toto R., and Palmer B.F. Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease. Am J Nephrol 28 (2008) 372-380
28. Mogensen C.E., Neldam S., Tikkanen I., et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 321 (2000) 1440-1444
29. Andersen N.H., Poulsen P.L., Knudsen S.T., et al. Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes. Diabetes Care 28 (2005) 273-277
30. Nakao N., Yoshimura A., Morita H., et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 361 (2003) 117-124
31. Bidani A. Controversy about COOPERATE ABPM trial data. Am J Nephrol 26 (2006) 629-632
32. Kunz R., Wolbers M., Glass T., et al. The COOPERATE trial: a letter of concern. Lancet 371 (2008) 1575
33. MacKinnon M., Shurraw S., Akbari A., et al. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis 48 (2006) 8-20
34. Kunz R., Friedrich C., Wolbers M., et al. Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease. Ann Intern Med 148 (2008) 30-48
35. Catapano F., Chiodini P., De Nicola L., et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression. Am J Kidney Dis 52 (2008) 475-485
36. Parfrey P.S. Inhibitors of the renin-angiotensin system: Proven benefits, unproven safety. Ann Intern Med 148 (2008) 76-77
37. Bakris G.L., Ruilope L., Locatelli F., et al. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int 72 (2007) 879-885
38. Menne J., Farsang C., Deak L., et al. Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial. J Hypertens 26 (2008) 1860-1867
39. Forclaz A., Maillard M., Nussberger J., et al. Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor?. Hypertension 41 (2003) 31-36
40. Berl T. Maximizing inhibition of the renin-angiotensin system with high doses of converting enzyme inhibitors or angiotensin receptor blockers. Nephrol Dial Transplant 23 (2008) 2443-2447
41. Department of Veterans Affairs. VA NEPHRON-D Study (CSP#565). http://clinicaltrials.gov/ct2/results?term=NCT00555217 Accessed October 12, 2008
42. Kazi D., and Deswal A. Role and optimal dosing of angiotensin-converting enzyme inhibitors in heart failure. Cardiol Clin 26 (2008) 1-14
43. Brown N.J. Aldosterone and end-organ damage. Curr Opin Nephrol Hypertens 14 (2005) 235-241
44. Pitt B., Zannad F., Remme W.J., et al., Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (1999) 709-717
45. Pitt B., Remme W.J., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
46. Remuzzi G., Cattaneo D., and Perico N. The aggravating mechanisms of aldosterone on kidney fibrosis. J Am Soc Nephrol 19 (2008) 1459-1462
47. Juurlin D.N., Mamdani M.M., Lee D.S., et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351 (2004) 543-551
48. Staessen J., Li Y., and Richart T. Oral renin inhibitors. Lancet 368 (2006) 1449-1456
49. Uresin Y., Taylor A.A., Kilo C., et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 8 (2007) 190-198
50. Oparil S., Yarrows S.A., Patel S., et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 370 (2007) 221-229
51. Parving H.H., Persson F., Lewis J.B., et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358 (2008) 2433-2446
52. Birkenhager W.H., and Staessen J.A. Dual inhibition of the renin system by aliskiren and valsartan. Lancet 370 (2007) 195-196
53. Ingelfinger J.R. Aliskiren and dual therapy in type 2 diabetes mellitus. N Engl J Med 358 (2008) 2503-2505
54. Gaddam K.K., and Oparil S. Renin inhibition: should it supplant ACE inhibitors and ARBs in high risk patients?. Curr Opin Nephrol Hypertens 17 (2008) 484-490
55. Azizi M., Linhart A., Alexander J., et al. Pilot study of combined blockade of the renin-angiotensin system in essential hypertensive patients. Hypertens 18 (2000) 1139-1147
56. Stergiou G.S., Skeva I.I., Baibas N.M., et al. Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension. Cardiovasc Pharmacol 35 (2000) 937-941
57. Weir M.R., Smith D.H.G., Neutel J.M., and Bedigian M.P. Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake. Am J Hypertens 14 (2001) 665-671
58. Weir M.R., Weber M.A., Neutel J.M., et al., ACTION Study Investigators. Efficacy of candesartan cilexetil as add-on therapy in hypertensive patients uncontrolled on background therapy: a clinical experience trial. Am J Hypertens 14 (2001) 567-572
59. Anan F., Takahashi N., Ooie T., et al. Effects of valsartan and perindopril combination therapy on left ventricular hypertrophy and aortic arterial stiffness in patients with essential hypertension. Eur J Clin Pharmacol 61 (2005) 353-359
60. Petrovic J., Petrovic D., Vukovic N., et al. Ventricular and vascular remodeling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients. J Int Med Res 33 suppl 1 (2005) 39A-49A
61. McKelvie R.S., Yusuf S., Pericak D., et al., The RESOLVD Pilot Study Investigators. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. Circulation 100 (1999) 1056-1064
62. Baruch L., Anand I., Cohen I.S., et al., Vasodilator Heart Failure Trial (V-HeFT) Study Group. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Circulation 99 (1999) 2658-2664
63. Hamroff G., Katz S.D., Mancini D., et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 99 (1999) 990-992
64. Murdoch D.R., McDonagh T.A., Farmer R., et al. ADEPT: addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects. Am Heart J 141 (2001) 800-807
65. Mario Negri Institute for Pharmacological Research. Preventing ESRD in Overt Nephropathy of Type 2 Diabetes (VALID). http://clinicaltrials.gov/ct2/results?term=NCT00494715 Accessed October 12, 2008
66. Nanfang Hospital. Safety of Dual Blockage of Renin-Angiotensin System in Patients With Advanced Renal Insufficiency (SDBRAS). http://clinicaltrials.gov/ct2/results?term=NCT00630708 Accessed October 12, 2008
67. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Boehringer Ingelheim Pharmaceuticals, Merck, Polycystic Kidney Disease Foundation. HALT Progression of Polycystic Kidney Disease (HALT PKD). http://clinicaltrials.gov/ct2/results?term=NCT00283686 Accessed October 12, 2008